Medication info

Hivandron Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Humedics Co., Ltd.
Appearance
A colorless, transparent solution in a colorless, transparent glass prefilled syringe, with a single-use syringe needle attached.
Packaging
3 milliliters/prefilled syringe
Approval status
Active

MFDS item code 202000457 · Notified 2020.01.29

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should receive calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment with serum creatinine of 200 µmol/L(2.3mg/dL) or less, or creatinine clearance of 30ml/min or higher. There is insufficient clinical experience in patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance below 30ml/min; therefore, administration of this medicine is not recommended. Elderly No dose adjustment is required.
Child administration
Efficacy and safety in children aged 18 years and younger have not been studied.

Ingredients

Manufacturer
Humedics Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis that occurs in postmenopausal women. Osteoporosis is a condition in which bones become weak and have a high risk of fractures, particularly occurring in women due to decreased estrogen levels after menopause. This medication helps to prevent bone loss and increase bone density, thereby reducing the risk of fractures. It improves bone health and enhances the quality of life. Therefore, it is effective in the treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Administer 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should receive calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment with serum creatinine of 200 µmol/L(2.3mg/dL) or less, or creatinine clearance of 30ml/min or higher. There is insufficient clinical experience in patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance below 30ml/min; therefore, administration of this medicine is not recommended. Elderly No dose adjustment is required.

Child administration

Efficacy and safety in children aged 18 years and younger have not been studied.

Precautions

This medication must be administered intravenously and care should be taken to avoid injecting into arteries or around the veins, as this may cause tissue damage. It should not be administered to patients who are allergic to this drug or its components and to untreated hypocalcemia patients. In clinical trials with long-term use of this drug, side effects such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, arthralgia, myalgia, headache, rash, and fatigue have been reported. When administered via injection, temporary flu-like symptoms (arthralgia, myalgia, fever, chills, fatigue, etc.) may occur but most are mild and resolve without treatment. Before administering this medication, it is important to treat hypocalcemia and metabolic disorders of bones and minerals, and to ensure adequate intake of calcium and vitamin D. During osteoporosis treatment, severe bone, joint, and muscle pain may occur, and if symptoms arise, immediate consultation with healthcare professionals is required. Reports of osteonecrosis of the jaw have been noted; therefore, especially in cancer patients or those needing dental treatment, an oral examination should be conducted before administration, and excessive dental interventions should be avoided during treatment. This drug is not metabolized by the liver and is excreted via the kidneys, so patients with impaired kidney function require regular monitoring. Women who are pregnant or breastfeeding should avoid using this drug, as its safety has not been established. In cases of overdose, careful monitoring is necessary as it may affect kidney and liver function, and appropriate treatment is needed if hypocalcemia or other complications arise. This medication should not be mixed with calcium-containing solutions, and syringes and needles should not be reused and must be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, uveitis, suprachoroiditis, scleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral fracture, intertrochanteric femoral fracture, osteonecrosis of the external auditory canal, jaw osteonecrosis, acute kidney failure, sensory loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air exposure and is best kept at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

A colorless, transparent solution in a colorless, transparent glass prefilled syringe, with a single-use syringe needle attached.

Package unit

3 milliliters/prefilled syringe

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.